AROCELL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.374 SEK | +0.54% |
|
-1.06% | -14.42% |
| 04-18 | Swedish Diagnostics Company AroCell Secures US Patent | MT |
| 02-22 | AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 61M 5.58M 446M | Sales 2025 * | 82.4M 7.54M 602M | Capitalization | 85.69M 7.84M 626M |
|---|---|---|---|---|---|
| Net income 2024 * | -51M -4.67M -373M | Net income 2025 * | -32M -2.93M -234M | EV / Sales 2024 * | 0.81 x |
| Net cash position 2024 * | 36M 3.29M 263M | Net cash position 2025 * | 38M 3.48M 278M | EV / Sales 2025 * | 0.58 x |
| P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-3.72
x | Employees | 22 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.36% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.54% | ||
| 1 week | -1.06% | ||
| Current month | +1.63% | ||
| 1 month | +5.65% | ||
| 3 months | -11.37% | ||
| 6 months | -28.35% | ||
| Current year | -14.42% |
1 week
0.36
0.38
1 month
0.330.40
Current year
0.300.52
1 year
0.300.70
3 years
0.306.70
5 years
0.307.55
10 years
0.3018.00
| Managers | Title | Age | Since |
|---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 30/11/18 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 31/12/21 | |
| Director/Board Member | 63 | 30/04/21 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 31/12/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.374 | +0.54% | 129 833 |
| 26/04/24 | 0.372 | +0.54% | 37,651 |
| 25/04/24 | 0.37 | +1.37% | 32,397 |
| 24/04/24 | 0.365 | -3.69% | 92,141 |
| 23/04/24 | 0.379 | +0.26% | 46,652 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 02:30 pm
More quotes
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.42% | 7.82M | |
| +2.37% | 42.75B | |
| +48.04% | 41.61B | |
| +11.94% | 41.34B | |
| -12.36% | 26.59B | |
| +8.52% | 25.49B | |
| -24.25% | 18.12B | |
| +30.20% | 12.24B | |
| -1.84% | 11.76B | |
| +7.64% | 11B |
- Stock Market
- Equities
- AROC Stock
